Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

Rhea-AI Summary

Aclarion (Nasdaq: ACON, ACONW) will participate in the 38th Annual ROTH Conference March 22-24, 2026, in Dana Point, CA to meet institutional investors and analysts.

CEO Brent Ness will hold one-on-one meetings to discuss progress advancing Nociscan, the company’s MR spectroscopy platform, and emphasize a strong balance sheet, no debt, and plans to expand adoption in the UK and US.

News Market Reaction – ACONW

+28.70%

+28.70% Session close to close

In the Mar 17 session, ACONW gained 28.70%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +28.7% in the session following this news. A strong positive reaction aligns with r...

Analysis

The stock surged +28.7% in the session following this news. A strong positive reaction aligns with recent patterns where upbeat Aclarion updates, including Nociscan growth and extended cash runway into 2028, have sometimes triggered outsized gains (such as a 40.28% move on a prior outlook). Investors have previously responded to visibility on financing and clinical timelines. However, warrant structure, small float, and prior post-news pullbacks after events like the -6.18% move following a financing could pose reversal risk.

Key Figures

Common-stock financing: $10.4 million Cash balance: $21.6 million Cash balance: $12.0 million +5 more

8 metrics

Common-stock financing $10.4 million Common-stock-only financing closed Jan 2026

Cash balance $21.6 million Cash as of Jan 12, 2026 after financing

Cash balance $12.0 million Cash as of Dec 31, 2025 with debt-free balance sheet

Fully diluted shares 2,882,371 Fully diluted shares outstanding noted in 2026 shareholder letter

Scan volume growth +69% YoY 2025 annual Nociscan scan volumes vs prior year

Q4 volume growth +114% YoY Q4 2025 Nociscan volumes vs prior-year quarter

Q2 2025 revenue $19,319 Quarter ended June 30, 2025, up 76% YoY

Q2 2025 net loss $1.60 million Net loss for quarter ended June 30, 2025

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 12	Conference participation	Positive	+8.1%	CEO meetings at LSI USA 2026 to discuss Nociscan progress and partnerships.
Feb 05	Shareholder letter	Positive	+3.1%	2026 shareholder letter outlining CLARITY timeline and cash runway into 2028.
Feb 03	Commercial expansion	Positive	-2.2%	Agreement with Source Healthcare to integrate Nociscan and generate real-world data.
Jan 13	Financing & runway	Positive	-6.2%	Common-stock financing boosting cash to $21.6M and extending runway into 2028.
Jan 08	Corporate outlook	Positive	+40.3%	2026 outlook with strong Nociscan volume growth and debt-free cash position.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Aclarion news has generally been positive, but market reactions have been mixed, with balance sheet strengthening drawing some selling while operational updates and outlooks often coincided with gains.

Recent Company History

Over the past few months, Aclarion has highlighted balance-sheet strengthening, operational momentum, and investor-outreach efforts. A January update reported 2025 scan volumes up strongly and a debt-free cash position, followed by a $10.4 million financing that lifted cash to $21.6 million. Subsequent news focused on Nociscan adoption, a shareholder letter detailing the CLARITY trial, and CEO participation at LSI USA 2026. Today’s ROTH conference participation continues this pattern of investor engagement and emphasis on Nociscan progress.

Key Terms

biomarkers, augmented intelligence, mr spectroscopy, form 4, +3 more

7 terms

biomarkers medical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

augmented intelligence technical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help"

Augmented intelligence combines human skills with advanced technology to enhance decision-making and problem-solving. It acts like a helpful partner that provides insights and suggestions, allowing people to make better choices more quickly. For investors, this means smarter analysis, improved efficiency, and the ability to respond to market changes with greater confidence.

mr spectroscopy medical

"Nociscan, the company’s proprietary MR spectroscopy platform designed to help physicians"

MR spectroscopy is a scientific technique that uses magnetic fields and radio waves to analyze the chemical composition of materials, including biological tissues. It helps researchers identify and measure the presence of different molecules, providing insights into health, disease, or material properties. For investors, understanding MR spectroscopy can be important when evaluating innovations in medical technology or pharmaceutical developments that may impact healthcare markets.

form 4 regulatory

"reported an option grant on a Form 4 filed 09/03/2025 for a transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

form 3 regulatory

"filed an initial Form 3 reporting event dated 09/02/2025."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

10-q regulatory

"[10-Q] Aclarion, Inc. Warrant Quarterly Earnings Report"

A 10-Q is a company’s required quarterly filing with U.S. regulators that provides updated financial statements, management discussion of results, and disclosures about risks, legal matters and operational changes. Think of it as a quarterly report card and progress update that lets investors track recent performance, spot trends or warning signs between annual reports, and make informed buy/sell decisions based on the latest verified financial and business information.

View in glossary

8-k regulatory

"[8-K] Aclarion, Inc. Warrant Reports Material Event"

An 8-K is a public report companies must file with the U.S. Securities and Exchange Commission to disclose major events or changes that shareholders should know about, such as leadership changes, mergers, financial surprises, or legal developments. It matters to investors because it acts like a breaking-news alert for a company’s health and prospects—providing timely facts that can affect stock value and investment decisions.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will participate in the 38th Annual ROTH Conference, March 22-24, 2026, in Dana Point, CA.

During the conference, CEO Brent Ness will engage in one-on-one meetings with institutional investors and analysts to discuss the company’s progress advancing Nociscan, the company’s proprietary MR spectroscopy platform designed to help physicians identify painful discs in patients suffering from chronic low back pain.

“We look forward to engaging with the investment community at ROTH to share the progress we are making and the important catalysts ahead for Aclarion,” said Brent Ness, CEO of Aclarion. “With a strong balance sheet, no debt, and a focused strategy to expand adoption of Nociscan in both the UK and US, we believe we are well positioned to execute on the significant opportunity ahead.”

To schedule a 1-on-1 meeting with Mr. Ness during the ROTH conference, please email: ksmith@pcgadvisory.com.

For more News from Aclarion, please visit: Latest News

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, an initial interim data readout is expected to be internally available at the end of Q3, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

FAQ

When will Aclarion (ACON) present at the 38th Annual ROTH Conference in 2026?

Aclarion will participate March 22-24, 2026 at the ROTH Conference in Dana Point, CA. According to Aclarion, CEO Brent Ness will hold one-on-one investor meetings to discuss Nociscan progress and upcoming catalysts.

What will Aclarion (ACON) discuss with investors at ROTH Conference March 2026?

Aclarion plans to discuss progress advancing Nociscan and near-term catalysts for the business. According to Aclarion, conversations will cover adoption plans in the UK and US and the company’s balance sheet position.

How can investors schedule a one-on-one meeting with Aclarion CEO Brent Ness at ROTH 2026?

Investors can schedule a 1-on-1 meeting by emailing ksmith@pcgadvisory.com to arrange time with Brent Ness. According to Aclarion, meetings are intended for institutional investors and analysts during March 22-24.

What is Nociscan and why will Aclarion (ACON) highlight it at the ROTH Conference?

Nociscan is Aclarion’s proprietary MR spectroscopy platform designed to identify painful spinal discs. According to Aclarion, the company will discuss clinical utility, adoption plans, and commercialization progress with investors.

What financial position will Aclarion (ACON) emphasize at the March 2026 ROTH Conference?

Aclarion will emphasize a strong balance sheet and that it carries no debt. According to Aclarion, this financial position supports its strategy to expand Nociscan adoption in the UK and US.

How can patients or providers find a Nociscan center after Aclarion’s ROTH participation?

Patients and providers can locate Nociscan centers via the company’s site map linked on its website. According to Aclarion, the site map lists current Nociscan locations and contact information for inquiries.